FDA Approves Polatuzumab Vedotin-Piiq Combination for DLBCL Patients

The FDA granted accelerated approval to polatuzumab vedotin-piiq, a CD79b-directed antibody-drug conjugate, in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news